or Try an Advanced Search...

    Technical Analysis for ARVN - Arvinas, Inc.

    Grade Last Price % Change Price Change
    C 30.30 30.77% 7.13
    ARVN closed up 30.77 percent on Wednesday, December 6, 2023, on 4.4 times normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.
    4 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Up
    Historical ARVN trend table...
    Date Alert Name Type % Chg
    Crossed Above 200 DMA Bullish 0.00%
    Expansion Breakout Bullish Swing Setup 0.00%
    Pocket Pivot Bullish Swing Setup 0.00%
    Volume Surge Other 0.00%
    Wide Range Bar Range Expansion 0.00%
    Parabolic Rise Strength 0.00%
    Multiple of Ten Bullish Other 0.00%
    Wide Bands Range Expansion 0.00%
    Above Upper BB Strength 0.00%
    Gapped Up Strength 0.00%
    Older End-of-Day Signals for ARVN ...

       Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

    Alert Time
    Possible Pocket Pivot about 18 hours ago
    60 Minute Opening Range Breakout about 21 hours ago
    Rose Above Upper Bollinger Band about 22 hours ago
    2x Volume Pace about 22 hours ago
    1.5x Volume Pace about 22 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    ARVN Chart by TradingView
    Basic chart:

    Profile

    Arvinas Inc. is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Arvinas uses its proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC™ protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Biology Disease Genetics Proprietary Technology Metabolism Chimera

    Is ARVN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Dec 6 Jefferies upgrades Arvinas to buy in wake of positive ARV-471 data
    Dec 6 Arvinas stock jumps 30% amid positive data for breast cancer drug
    Dec 6 Pfizer (PFE), Arvinas Post Upbeat Data From Breast Cancer Study
    Dec 6 Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program
    Dec 5 Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program
    Dec 1 Does Arvinas, Inc. (ARVN) Have the Potential to Rally 145.52% as Wall Street Analysts Expect?
    Nov 28 Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium
    Nov 27 Arvinas announces private placement to raise $350M
    Nov 27 Arvinas Announces Oversubscribed $350 Million Private Placement
    Nov 24 Arvinas: Protein Degradation Pioneer Presents An Intriguing Speculative Buy Opportunity
    See more ARVN news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 39.31
    52 Week Low 13.57
    Average Volume 642,363
    200-Day Moving Average 24.21
    50-Day Moving Average 18.79
    20-Day Moving Average 21.38
    10-Day Moving Average 23.99
    Average True Range 2.08
    RSI (14) 74.09
    ADX 32.87
    +DI 47.72
    -DI 17.09
    Chandelier Exit (Long, 3 ATRs) 24.72
    Chandelier Exit (Short, 3 ATRs) 20.29
    Upper Bollinger Bands 28.54
    Lower Bollinger Band 14.22
    Percent B (%b) 1.12
    BandWidth 66.99
    MACD Line 2.13
    MACD Signal Line 1.51
    MACD Histogram 0.6183
    Fundamentals Value
    Market Cap 1.23 Billion
    Num Shares 40.5 Million
    EPS -7.16
    Price-to-Earnings (P/E) Ratio -4.23
    Price-to-Sales 39.19
    Price-to-Book 4.98
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 40.33
    Resistance 3 (R3) 39.44 35.20 38.66
    Resistance 2 (R2) 35.20 32.65 35.65 38.10
    Resistance 1 (R1) 32.75 31.07 33.98 33.64 37.54
    Pivot Point 28.52 28.52 29.13 28.96 28.52
    Support 1 (S1) 26.07 25.96 27.29 26.96 23.06
    Support 2 (S2) 21.83 24.39 22.28 22.50
    Support 3 (S3) 19.38 21.83 21.94
    Support 4 (S4) 20.27